Barr E S & Co. Takes $586,000 Position in Pfizer Inc. $PFE

Barr E S & Co. bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 23,524 shares of the biopharmaceutical company’s stock, valued at approximately $586,000.

Several other large investors have also recently made changes to their positions in PFE. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $29,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. HSBC boosted their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Finally, Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.84.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.31 on Friday. The firm has a 50-day simple moving average of $26.98 and a 200-day simple moving average of $26.19. The stock has a market capitalization of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52 week low of $22.45 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.